Memorandum of Collaboration (MoC) with Suzhou Ronnsi Pharma Co., Ltd
15 July 2022
Memorandum of Collaboration (MoC) with Suzhou Ronnsi Pharma Co., Ltd
Pharmaniaga LifeScience Sdn Bhd (PLS), a wholly-owned subsidiary of Pharmaniaga Berhad inked a Memorandum of Collaboration (MoC) with Suzhou Ronnsi Pharma Co., Ltd to commercialise a halal ovine-based (sheep and goat) anti-coagulant blood clot thinner on 15 July 2022 at Royale Chulan Damansara. The MoC was signed by Pharmaniaga Group Managing Director Datuk Zulkarnain Md Eusope, while Suzhou Ronnsi was represented by Chief Executive Director Mr. Yao Yiming and witnessed by Datuk Seri Zainal Abidin Mohd Rafique, Chairman of Pharmaniaga, Dr Mohd Ghows Mohd Azzam Director of Malaysia Genome and Vaccine Institute, En Hairol Ariffein Sahari Chief Executive Officer of Halal Development Corporation Berhad and Mr Choon Teo, Technical Director of Suzhou Ronnsi. With the MoC, Pharmaniaga will be the exclusive product registration holder, marketing and distribution partner with Ronnsi as the product owner and developer. Also present were En. Zulkifli Jafar, Group Executive Director, En. Mohamed Iqbal Abdul Rahman, Group Deputy Managing Director, of Pharmaniaga, En. Hanifsofian Alias, Chief Industry Development Officer of Halal Development Corporation Berhad, Prof Dr Irwan Mohd Subri, Director of The Institute of Fatwa and Halal, Islamic Science University of Malaysia and senior officials of Pharmaniaga.
